

From Tunisian ethnomedicine : Uroprotective activity of Aloe vera plant extract against Cyclophosphamide and Buthionine sulfoximine induced toxicities

Bechr Hamrita, MD^{*1}, Kamel Rouissi, MD^{*1}, Soumaya Kouidi, MD¹, Mohamed Cherif, MD², Amel Benammar Elgaaied, MD¹

(1) Laboratory of Genetics, Immunology, and Human Pathology, Faculty of Sciences of Tunis, University of El Manar I, 2092, Tunis, Tunisia

(2) Department of Urology, Hospital of Charles Nicolle, Tunis, Tunisia

✉ Corresponding Author: Dr Bechr Hamrita, Laboratory of Genetics, Immunology and Human Pathology Faculty of sciences of Tunis, University of El Manar I, 2092, Tunis, Tunisia.
E-mail: bechrhamrita@yahoo.fr

*The authors Bechr Hamrita and Kamel Rouissi contributed equally in this work.

Key words: Cyclophosphamide, Buthionine sulfoximine, Urotoxicity, Antioxidants.

ISSN: 2070-254X

Abstract

Cyclophosphamide (CP) and buthionine-SR-sulfoximine (BSO) are commonly used anti-cancer drugs which cause toxicity by their reactive metabolites. The present study was undertaken to investigate the effects of pre-treatment with an *Aloe vera* plant extract on the urotoxicity induced by acute doses of CP and BSO using a Swiss albino mice model. The modulation of toxicity was evaluated by measuring lipid peroxidation (LPO) and antioxidants in the urinary bladder of the animals. The findings revealed that *Aloe vera* induced remarkable protective effects in terms of both LPO and enzymatic antioxidant activities. The CP-treated mice were noted to undergo significant decreases in the activities of glutathione S-transferase (GST), glutathione reductase (GR), glutathione peroxidase (GP), and catalase (CAT) when compared to the controls. The levels of reduced glutathione (GSH) also decreased with an increase in LPO in the CP-treated animals and BSO treatment exerted an additive toxic effect in the CP-treated animals. Pre-treatment with the *Aloe vera* herbal extract restored all enzymatic activities back to normal, thus confirming its overall protective effect against the toxic effects of CP and BSO. The restoration of GSH through treatment with *Aloe vera* may play an important role in the reversal of CP-induced apoptosis and free radical mediated LPO in urinary bladder. Due to its widespread availability in nature and relative lack of toxicity, the *Aloe vera* plant extract presented in the current study could be considered a potential strong candidate for future applications as an adjuvant to cancer chemotherapies.

Introduction

Bladder cancer is one of the most frequently occurring cancers in the world. According to the current estimates by the American Cancer Society (ACS), this disease is the fourth most common cancer in men and eighth leading cause of death in women in the United States. Although several treatments and therapies, including surgery, radiation, and chemotherapy have been used to reduce and prevent the rising death rates caused by this deadly disease, a number of serious concerns have often been voiced with respect to the troublesome side effects

associated with each type of treatment.

Cyclophosphamide (CP) and buthionine-SR-sulfoximine (BSO) are two of the leading medications often prescribed for the treatment of cancer. CP is an effective alkylating agent widely used in the anti-neoplastic therapy of a variety of cancers, including lymphoma, myeloma, and chronic lymphocytic leukaemia [1]. CP intake has, however, frequently been associated with a variety of troublesome side effects, including alopecia, cardiac damage, gonadal atrophy, hemorrhagic cystitis, hematopoietic depression, nausea, vomiting, and carcinogenicity as well as lung toxicity [2,3]. It has also been reported to involve a number of urological side effects, such as transient irritating voiding symptoms, including dysuria, hemorrhagic cystitis, bladder fibrosis, necrosis, contracture, and vesicometral flux [4].

The accumulation of CP reactive metabolites in the urinary bladder has also been reported to induce reactive oxygen species (ROS) production, which cause peroxidative damage to the urinary bladder as well as to other vital organs [3]. Additionally, CP treatment has been described to bring about a decrease in the levels of reduced glutathione (GSH), which represents one of the most important organic molecules within the cell that determine its ability to suppress toxic substances, such as chemotherapeutic reactive metabolites [2,5,6].

In fact, GSH depletion is considered as an attractive strategy for the sensitization of tumour cells to certain chemotherapeutic agents. A number of reports suggested that BSO can be used effectively to reduce the level of GSH and may help restore the sensitivity of resistant tumours to alkylating agents. However, CP-induced immunosuppression may incite various types of infectious agents that have serious GSH depleting effects [7]. In other words, CP treatment might decrease the GSH content itself but the secondary infections associated with it might bring additional decreases in the levels of GSH. Accordingly, a patient undergoing CP chemotherapy would need an excessive supply of GSH-restoring antioxidants or compounds that induce GSH production.

In this context, a number of GSH-inducing compounds have been reported to be effective CP toxicity reducers in animals [8]. Several extracts from plant origin have been described to exert valuable protective and/or restorative effects on CP-induced decreases of GSH [9]. Of particular interest to the aims of the present study, Aloe plants have long been used to treat a wide array of ailments and

diseases. *Aloe barbadensis* Miller, commonly known as *Aloe vera*, is one of the most popular varieties of Aloe plants whose healing properties are immense [10]. It belongs to the Liliaceae family, of which about 360 species exist. It is a cactus-like plant that grows readily in hot, dry climates and, due to its great curative properties, has often been cultivated in large quantities. Two distinct preparations of Aloe plants are most used medicinally. The leaf exudates (*aloe latex*), which is a yellow, bitter liquid derived from the skin of the Aloe leaf, has strong stimulatory and laxative properties and has, therefore, been commonly used for the treatment of diabetes, coughs, wounds, ulcers, cancer, headaches, arthritis, among various other conditions [11]. The mucilaginous gel (*Aloe gel*), which is a clear colourless semi-solid gel extracted from the leaf parenchyma, has attractive immunomodulatory properties, and has, therefore, been commonly used as a remedy against a variety of skin disorders [12].

Public interest in *Aloe vera* has grown quickly, and considerable research has been conducted over the past few decades to explore the various components and properties of this herbal medicine and to find out clues as to its potential cosmetic, pharmaceutical, and therapeutic applications. In fact, although scientific evidence for the cosmetic and therapeutic effectiveness of *Aloe vera* is very limited, various cosmetic and medicinal formulations have been made from *Aloe latex* and *Aloe gel*. *Aloe vera* is rich in antioxidants and various nutrients. It contains lignin, saponins, and mono and polysaccharides (including Acemannan). The consumption of *Aloe vera* leaf formulations has been shown to display anti-arthritis, anti-rheumatoid, and anti-cancer properties as well as anti-diabetic benefits [13,14]. It has been commonly used for the topical treatment of a variety of ailments and disorders, including chronic wounds, thermal injuries, skin infections, inflammations, oral ulcers, and psoriasis as well as for the prevention of ultraviolet (UV)-induced immunosuppression [15,16].

Considering its widespread availability in nature, relative richness in antioxidants, and distinguished healing properties, the present study was undertaken to investigate the effects of the oral administration of an *Aloe vera* plant extract in terms of antioxidant and lipid peroxidation (LPO) activities in the urinary bladder of CP and BSO treated mice that were pre-disposed or concomitantly exposed to a GSH reducing agent in the form of either an infection or antibiotic use.

Materials and Methods

Plant extracts (PE)

The present study used a total aqueous semisolid extract of *Aloe vera* that was purchased from the Plant Extract Division of the local Central Pharmacy, Tunisia. The plant extract (PE) had moisture and ash contents of 12% and 8%, respectively. The pH of 10% aqueous solution of extract was 4.6. The authenticity of the extract was certified by the manufacturer's expert taxonomist.

Chemicals

Cyclophosphamide monohydrate (2-(bis-(2-chloroethyl) amino) tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate); CAS 6055-19-2; BSO (L-buthionine-SR-sulfoximine); and CAS 5072-26-4 were purchased from Sigma-Aldrich Co., St. Louis, MO, USA.

Animals

The experimental essays of the present study were conducted on male Swiss albino mice (25 ± 2 g) provided by the animal service of the Pasteur Institute of Tunis, Tunisia. All care and animal handling procedures were performed in accordance with the guidelines of the Institutional Animal Ethics Committee

(IAEC). The animals were bred and maintained under standard laboratory conditions (temperature 25 ± 2 °C; photoperiod of 12 h). Commercial pellet diet and water were given *Ad libitum*.

Dosage and experimental groups

BSO, CP and plant extract of *Aloe vera* were suspended in normal saline. The animals were divided into seven groups, Groups I–VII, of at least six mice each. Group I (Control) referred to control mice that were administered normal saline p.o. for 10 days and a single intra peritoneal (i.p.) injection on the 10th day of treatment. Group II (BSO) referred to the mice that received BSO (500 mg/kg body wt) and to which a single i.p. injection was administered on the 10th day. Group III (CP) designated the mice that received CP (50 mg/kg body wt.) and a single i.p. dose on the 10th day. Group IV (BSO + CP) referred to animals that were administered BSO i.p. 5 h before CP administration. Group V (CP + PE) referred to animals that were administered plant extract for 10 days and a single i.p. injection of CP on the 10th day. Group VI (BSO + PE) designated animals that were given plant extract treatment (100 mg/kg body wt.) p.o. for 10 days and a single i.p. injection of BSO on the 10th day. Group VII (BSO + CP + PE) referred to the animals that were administered plant extract for 10 days and CP and BSO on the 10th day. Dosing was performed in such a way that all of the animals could be sacrificed on the same day, i.e., day 11. The selection of BSO and CP doses was based on pilot experiments that involved the assay of a wide range of doses and on data provided from previously published reports [9,17].

Biochemical investigations

Upon the completion of the treatment, the animals were sacrificed under mild anesthesia and their bladders were removed. The bladder tissue was homogenized in chilled phosphate buffer (0.1 M, pH 7.4) using a Potter homogenizer. The homogenate was centrifuged at 10,500g for 30 min at 4 °C to obtain the post-mitochondrial supernatant (PMS), which was used for the biochemical measurements as described below.

1. Lipid peroxidation

LPO was measured using the procedure of previous work [18]. The assay mixture consisted of 0.67% thiobarbituric acid; TBA (Sigma-Aldrich), 10 mM; butylated hydroxy toluene BHT (Sigma-Aldrich), 1%; ortho-phosphoric acid (Sigma-Aldrich); and tissue homogenate in a total volume of 3 ml. The rate of LPO was expressed as nmol of TBA reactive substances (TBARS) formed/h/g of tissue using molecular extinction coefficient (ϵ) of 1.56×10^5 M⁻¹ cm⁻¹.

2. Measurement of GSH

GSH content was measured in the PMS of urinary bladder by the method described in previous work [9]. PMS (1ml) was precipitated with 1 ml of 4% sulfosalicylic acid (Sigma-Aldrich). The samples were incubated at 4 °C for 1 h and then centrifuged at 1200g for 15 min at 4 °C. The assay mixture consisted of 0.2 ml of filtered aliquot, 2.6 ml of sodium phosphate buffer (0.1 M, pH 7.4), and 0.2 ml 100 mM DTNB (dithio-bis-2-nitrobenzoic acid, Sigma-Aldrich) in a total volume of 3 ml. The absorbance of the reaction product was measured at 412 nanometer (nm), and the results were expressed as nmol GSH/g of tissue.

3. Antioxidant enzyme measurements

Glutathione-S-transferase (GST) activity was assayed using the method described previously [9]. The reaction mixture consisted of 1.675 ml sodium phosphate buffer, 0.2 ml of 1 millimolar (mM) GSH (Sigma-Aldrich), 0.025 ml of 1 mM CDNB (1-chloro-2,4-dinitrobenzene, Sigma-Aldrich), and 0.1 ml of PMS in a total volume of 2 ml. The change in absorbance was recorded at 340 nm and the

enzyme activity calculated as nmol CDNB conjugates formed/min/mg protein using epsilon (ϵ) of $9.6 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$. GR (glutathione reductase) activity was assayed by the method of Sharma et al. (2001). The assay mixture consisted of 1.6 ml sodium phosphate buffer, 0.1 ml of 1 mM ethylenediamine tetra acetic acid disodium salt (EDTA, Sigma-Aldrich), 0.1 ml NADPH (nicotinamide adenine dinucleotide phosphate reduced, Sigma-Aldrich), and 0.1 ml oxidized glutathione (Sigma-Aldrich) and PMS (0.1 ml) in total volume of 2 ml.

Enzyme activity measured at 340 nm was calculated as nmol NADPH oxidized/min/mg of protein, using ϵ of $6.22 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$. Glutathione Peroxidase (GP) activity was assayed using the method of Sharma, (2001). The assay mixture consisted of 1.49 ml sodium phosphate buffer, 0.1 ml EDTA (1 mM), 0.1 ml sodium azide (1 mM, Central Pharmacy of Tunis, Tunisia), 0.1 ml of 1 mM GSH (Sigma-Aldrich), 0.1 ml NADPH (0.02 mM), 0.01 ml of 0.25 mM hydrogen peroxide (H_2O_2 , CDH Chemicals), and 0.1 ml PMS in a total volume of 2 ml. Oxidation of NADPH was recorded spectrophotometrically at 340 nm. The enzyme activity was calculated as nmol NADPH oxidized/min/mg of protein using ϵ of $6.22 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$. CAT (catalase) activity was assayed using the method of Haque, (2003). The assay mixture consisted of 1.95 ml phosphate buffer, 1 ml H_2O_2 (0.09 M), and 0.05 ml of PMS at a final volume of 3 ml. Change in absorbance was recorded kinetically at 240 nm. CAT activity was calculated in terms of nmol H_2O_2 consumed/min/mg of protein.

4. Protein measurement

Protein was measured by the method described in previous work [19].

Statistical analysis

Single factor one-way analysis of variance (ANOVA) was performed to determine significant differences in results of various groups. The statistical significance level was set at P values < 0.05 . A Student-Newman-Keuls test was then carried out to analyze and compare the significance of the different treatment groups. The values were expressed as mean \pm SE.

Results

No mortalities and significant changes in the body weight of the different groups of animals were recorded during the treatment.

1. Lipid peroxidation (LPO)

The findings revealed that BSO treatment brought about a significant increase ($P < 0.01$) in the LPO levels in the bladder over the control values (Fig. 1). The administration of CP was also noted to induce LPO in significant way. Likewise, the cumulative effect of BSO + CP resulted in significant increase in the LPO as compared to Group I (control). BSO + CP group (Group IV) also underwent a significant ($P < 0.01$) increase in the levels of LPO when compared the CP group (Group III) alone (Fig. 1). The animals pre-treated with *Aloe vera* plant extract (PE) and subsequently exposed to BSO (BSO + PE), on the other hand, were noted to undergo a significant ($P < 0.01$) reduction in terms of LPO levels in the bladder. When the values obtained for the CP + PE group (Group V) were compared to those of the CP group (Group II), PE treatment was also observed to significantly ($P < 0.05$) reduce the levels of LPO in the bladder. As illustrated in Figure 1, the comparison between the LPO values obtained for the LPO of BSO + CP group (Group IV) and those of the BSO + CP + PE group clearly shows a significant decrease ($P < 0.01$) in the case of the latter (Group VII).

2. Reduced glutathione

The findings revealed that, when compared to the control values (5 nmol GSH/g tissue), the BSO, CP and BSO + CP-treated groups underwent significant ($P < 0.01$) decreases of 2.5, 3.5 and 1.5 nmol GSH/g tissue in GSH, respectively (data generated for Cellular GSH of urinary bladder are shown in Fig. 2). Likewise and when compared to the CP group (Group III), the BSO + CP group (Group IV) showed a significant ($P < 0.01$) decrease in terms of GSH levels. As shown in Fig. 2, when the BSO and BSO + PE groups were compared, the GSH content of the latter was noted to undergo a significant increase ($P < 0.01$). Similarly, the GSH content in the bladder of the CP + PE group (Group V) showed a significant increase ($P < 0.01$) when compared to the group given only CP (Group III). When the GSH values obtained for the BSO + CP (Group IV) group were compared to those of the BSO + CP + PE group (Group VII), a significant ($P < 0.01$) restoration in GSH was recorded (Fig. 2).

3. Antioxidant enzymes

BSO and CP treatments were observed to induce significant ($P < 0.01$) decreases in terms of GST, GR, GP and CAT activities in the bladder when compared to the control group (Table 1). The BSO + CP group also showed an additive significant ($P < 0.01$) decrease in the activities of GST, GR, and GP when compared to the CP or control group. However, no significant difference was observed in terms of CAT activity between the animals of group IV (BSO + CP) and group III (CP). The activities of those antioxidant enzymes increased significantly ($P < 0.01$) in both the BSO + PE (Group VI) and the CP + PE (Group V) groups when compared to their respective controls, the BSO (Group II) and CP (Group III) groups (Table 1). The animals treated with PE and subsequently exposed to BSO + CP (Group VII, BSO + CP + PE treatment) displayed a significant increase ($P < 0.01$) in the activities of all the antioxidant enzymes when compared to the BSO + CP group (Group IV).

Discussion

Chemotherapeutic agents are known to influence the function of the urinary tract. Cyclophosphamide (CP) is an alkylating agent widely used in cancer chemotherapy. Its cytotoxic effects are the result of chemically reactive metabolites that alkylate DNA and protein, producing cross-links [2]. It has been reported that oxidative stress mediated disruption of redox balance after CP exposure generates biochemical and physiological disruptions [10]. Several studies indicate that CP has a pro-oxidant character, and that the generation of oxidative stress after CP administration leads to a decrease in the activities of antioxidant enzymes and an increase in lipid peroxidation (LPO) in the liver, lung, and serum of mice and rats [3]. Reactive oxygen species (ROS), such as the nitric oxide radical (NO), are included in the pathogenesis of CP-induced cystitis. It has also been reported that increases in ROS, such as NO, lead to bladder oedema, inflammation, and extravasation [20].

Despite its potent antitumor activity, CP-induced urotoxicity remains the major limiting step for its clinical application. Urotoxic effects of CP can be dose limiting and have proven fatal. Since the bladder is the site for the storage of urine, the concentration of CP toxic metabolites is higher in the bladder than in any other organ. However, the mechanisms that determine the individual susceptibility to CP and the mediation of bladder toxicity remain unclear.

Treatment with buthionine sulfoximine (BSO), a potent inhibitor of *r*-glutamylcysteine synthetase, has been reported to enhance the *in vitro* antitumor efficacy of a number of drugs, including CP, melphalan, adriamycin, daunomycin, and mitomycin C [21]. By inhibiting this essential enzyme, BSO

has the capacity to drastically reduce glutathione content. In fact, it has been shown in several animal model systems to enhance the cytotoxic effects of specific chemotherapeutic agents and radiation therapy [22]. BSO and other agents directed at modulating glutathione levels affect the content of this metabolite in normal tissues as well as in tumors. Several studies have shown that depletion of GSH after BSO treatment result in a variety of toxic effects, including cardiotoxicity, hepatic damage, and respiratory problems.

Considering the various toxic effects associated with CP treatment used alone or in combination with BSO, special attention has been given in recent research to the search for novel compositions for use as broad-spectrum chemoprotectants to help alleviate or prevent such damages. Such novel compositions could serve as adjuvants to chemotherapies to protect patients' normal cells from the toxicity associated with such therapies. In this respect, folk medicine seems to be gaining increasing respect from the medical research community. More succinctly, there is a growing tendency in recent research for the search of tumour-therapeutic agents of natural origins. In fact, although neither its active components nor mechanisms of action are fully understood, folk medicine has often been used with enormous success for the treatment of various diseases.

In this context, a number of natural products and compounds have been shown to reduce CP toxicity mainly due to their antioxidant action [8]. Several extracts from plant origin have been described to exert valuable protective and/or restorative effects on CP-induced decreases of GSH [9]. Of particular interest, the *Aloe vera* plant has often been reported to possess attractive healing properties. Accordingly, the present study was undertaken to investigate the effects of the oral administration of an *Aloe vera* plant extract in terms of antioxidant and lipid peroxidation (LPO) activities in the urinary bladder of CP and BSO treated mice that were pre-disposed or concomitantly exposed to a GSH reducing agent in the form of either an infection or antibiotic use.

The findings revealed that throughout the treatment no mortalities were recorded for the different experimental groups of animals, and that significant changes were observed in terms of their body weights. In fact, when the values pertaining to GSH reduction were compared, BSO was noted to exhibit more significant effects than CP. A difference of 42% was recorded between both agents, which, as previously reported in the literature, confirm that BSO is a more potent depletor of GSH than CP [23]. CP-induced depletion of GSH is primarily mediated by the interaction of its reactive metabolite, acrolein, with GSH [24]. Acrolein not only interacts with GSH but also with cysteine, which is one of the constituent amino acids of GSH [24]. Several reports in the literature have indicated that compounds containing free sulfhydryl groups may protect from the urotoxic effects of Cyclophosphamide. A number of sulfhydryl (-SH) compounds, and cysteine itself, have been observed to protect experimental animals from the toxic effects of CP [23].

The intra-peritoneal administration of CP was noted to significantly induce LPO in the bladder. In fact, lipid peroxidation is widely used as an indicator to reflect oxidative stress and cell membrane damage. Free radicals, such as superoxide anion and hydroxyl radical, exert their toxic effect by acting on DNA, membrane proteins, and lipids. CP-induced LPO has been reported in different tissues of exposed animals. In CP-induced LPO, the role of acrolein has also been implied [25]. It has been suggested that by binding to nucleophilic amino acids, acrolein could directly affect transcription as well as modulate this process through its ability to deplete GSH [24].

As far as BSO treatment was concerned, the findings revealed that it resulted in the depletion of GSH and the increase of LPO in the urinary bladder. The depletion of GSH is also reported to increase the susceptibility of cells to apoptosis [26]. A depletion of intracellular GSH has been described in a number of different apoptotic systems, with several studies showing that GSH loss in

cells undergoing apoptosis is the result of accelerated efflux rather than depletion by oxidation [27].

Moreover, when BSO and CP were administered together, an additive effect was observed in case of GSH and LPO among several other parameters. The purpose of using BSO along with CP was to study a likely scenario where the host is exposed to a combination of GSH depleting agents, including pathogens, and to assess whether the herbal extract treatment of *Aloe vera* has any modulatory effect on their commutative/additive effect.

In this study, pre-treatment with *Aloe vera* extract not only showed a marked protective effect with regards to CP urotoxicity but also played an efficient protective role for the animals treated with the CP + BSO combination (Group VII).

The pre-treatment with the *Aloe vera* extract was noted to restore the depleted GSH and other antioxidants and, at the same time, reduced the LPO levels in the bladder. In fact, CP-induced immunosuppression is likely to increase the incidence of infections that may deplete GSH, as many infectious agents are reported to deplete GSH [7]. Overall, the findings indicate that the herbal extract presented in the current study is a promising immunomodulatory herbal extract with powerful GSH restoring effects. This extract could, therefore, open new opportunities for the reduction of the adverse effects of CP and BSO cancer treatments.

In fact, the immunomodulatory effect of *Aloe vera* has previously been demonstrated in mice. Aloe-Emodin was found to alter the expression of a number of proteins involved in oxidative stress, cell-cycle arrest, anti-metastasis, and apoptosis [28]. Moreover, AE was capable of enhancing the intracellular level of reactive oxygen species (ROS). This may not unexpected since AE has a quinone structure that is highly redox active in nature and that can form a redox cycle with their semiquinone radicals, thus leading to the formation of ROS. AE was recently found to be able to induce DNA damage through excessive production of ROS in human lung carcinoma cells. This anticancer specificity further suggests that AE could be a potent chemotherapeutic agent or chemo-preventive compound. It is noteworthy that endothelial cells have recently been reported to be sensitive to AE [29]. This property was suggested to be useful for the modulation of angiogenesis as well as antitumor effects [29].

Moreover, the findings presented in the current work suggest that *Aloe vera* has a potent chemo-preventive potential for the inhibition of the toxicity processes by modulating lipid peroxidation and cellular antioxidant environments. The findings of the present study demonstrate that *Aloe vera* extract pre-treatment prevented CP urotoxicity that was primarily mediated by LPO and depleted GSH by reversing those effects.

In short, the present work is the first attempt to focus on the biological activities and bladder urotoxicity in Tunisia. In fact, the plant extract presented here showed a significant antioxidant potential in different assays in vivo. The findings provided ample support for the efficiency of the *Aloe vera* extract as a natural antioxidant agent. Due to its widespread availability in nature and relative lack of toxicity, this herbal extract could be considered a potential strong candidate for future applications as an adjuvant to cancer chemotherapies. Accordingly, further studies are currently underway in our laboratories to further explore this extract in terms of cell cycle regulatory activity and antioxidant activity, to further validate its efficacy as an anti-tumor agent, and to make its use suitable for potential pharmaceutical applications as a therapeutic agent.

Acknowledgements: This study was supported by the Tunisian Ministry of Higher Education and Scientific Research and Technology and the Tunisian Ministry of Public Health.

References

1. Baumann and Preiss R (2001). Cyclophosphamide and related anticancer drugs. *J. Chromatogr. B. Biomed. Sci. Appl.*, 764:173–192.
2. Fleming RE (1997). An overview of cyclophosphamide and ifosfamide pharmacology. *Pharmacotherapy.*, 17: 1465–45.
3. Patel J M, and Block E R (1985). Cyclophosphamide-induced depression of antioxidant defense mechanisms of the lung. *Exp. Lung. Res.*, 8: 153–165.
4. Levine LA, Richie JP (1989). Urological complications of cyclophosphamide. *J Urol*, 141: 1063-9.
5. Abd-Allah AR, Gado AM, Al-Majed AA, Al-Yahya AA, and Al-Shabanah OA (2005). Protective effect of taurine against cyclophosphamide-induced urinary bladder toxicity in rats. *Clin. Exp. Pharmacol. Physiol.*, 32: 167–172.
6. Ahmed A R, and Hombal S M (1984). Cyclophosphamide: Cytoxan, a review on relevant pharmacology and clinical uses. *J. Am. Acad. Dermatol.*, 11: 1115–1126.
7. Hung CR, and Wang PS (2004). Gastric oxidative stress and hemorrhagic ulcer in *Salmonella typhimurium*-infected rats. *Eur. J. Pharmacol.*, 491: 61–68.
8. Manesh C, and Kuttan G (2005). Effect of naturally occurring isothiocyanates in the inhibition of cyclophosphamide-induced urotoxicity. *Phytomedicine.*, 12: 487–493.
9. Haque R, Bin-Hafeez B, Parvez S, Pandey S, Sayeed I, Ali M (2003). Aqueous extract of walnut (*Juglans regia* L) protects mice against cyclophosphamide-induced biochemical toxicity. *Hum. Exp. Toxicol.*, 22: 473–480.
10. Moon E J, Lee Y M , Lee O H , Lee M J , Lee S K , Chung M H , Park Y I, Sung C K, Choi, JS , Kim K W (1999). A novel angiogenic factor derived from Aloe vera gel: beta-sitosterol, a plant sterol. *Angiogenesis.*, 3: 117-123.
11. Ghannam N, Kingston M, Al-Meshaal A, Tariq M, Parman NS, Woodhouse N (1986). The antidiabetic activity of aloes: preliminary clinical and experimental observations. *Horm. Res.*, 24: 288-294.
12. Capasso F, Gaginella T S (1997). *Laxatives: a practice guide*. Milan: Springer Italia.
13. Pecere T, Gazzola M V, Mucignat C, Parolin C, Vecchia F D, Cavaggioni A, Basso C (1996). Aloe vera gel. *J. Ethnopharmacol.*, 55: 69–75.
14. Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chochehajaroenporn O (1996). Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus. *Phytomedicine*, 3: 241–243.
15. Roesler J, Steinmuller C , Kiderlen A, Emmendorffer A, Wagner H, Lohmann-Matthes M L. (1991). Application of purified polysaccharides from cell cultures of the plant *Echinacea purpurea* to mice mediates protection against systemic infections with *Listeria monocytogenes* and *Candida albicans*. *Int. J. Immunopharmacol.*, 13: 27–37.
16. Byeon S W, Pelley RP, Ullrich SE, Waller TA, Bucana CD, Strickland FM (1998). Aloe barbadensis extracts reduce the production of interleukin-10 after exposure to ultraviolet radiation. *J. Invest. Dermatol.*, 110: 811–817.
17. Sharma N, Trikha P, Athar M, and Raisuddin, S (2001). Inhibition of benzo(a)pyrene- and cyclophosphamide-induced mutagenicity by *Cinnamomum cassia*. *Mutat. Res.*, 481: 179–188.
18. Mihara M, Uchiyama M (1978). Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. *Anal Biochem.*, 86(1): 271-8.
19. Lowry O, Rosebrough NJ, Randall RJ (1951). Protein measurement with Folin phenol reagent. *J. Biol. Chem.*, 193: 265–275.
20. Souza-Filho M V, Alves M V, Lima M M, Ballejo G, Queiroz FC, Ribeiro RA (1997). Involvement of nitric oxide in the pathogenesis of cyclophosphamide- induced hemorrhagic cystitis. *Am. J. Pathol.*, 50: 247–256.
21. Owls R F , Louie K O , Plowman J , Behrens B C , Fine RL, Dykes D (1987). Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine depletion of glutathione. *Biochem. Pharmacol.*, 36: 147-1531.
22. Biaglow J E, Varnes M E , Epp E R , Clark E P , Tuttle S W , and Held K D (1989) . Role of glutathione in the aerobic radiation response. *Int. J. Radiat. Oncol. Biol. Phys.*, 16:1311-1311.
23. Ishikawa M, Takayanagi Y, and Sasaki K (1989). Modification of cyclophosphamide-induced urotoxicity by buthionine sulfoximine and disulfiram in mice. *Res. Commun. Chem. Pathol. Pharmacol.*, 65 : 265–268.
24. Kehrer JP, and Biswal SS (2000). The molecular effects of acrolein. *Toxicol. Sci.*, 57: 6-15.
25. Adams J D, and Klaidrnan L K (1993). Acrolein induced oxygen radical formation. *Free. Radic. Biol. Med.*, 15: 187–193.
26. Mirkovic N, Voehringer D W, Story M D, McConkey D J, McDonnell TJ, and Meyn RE (1997). Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. *Oncogene.*, 15: 1461–1470.
27. Ghibelli L, Fanelli C, Rotilio G, Lafavia E, Coppola S, Colussi C (1998). Rescue of cells from apoptosis by inhibition of active GSH extrusion. *FASEB J.*, 12: 479-486.
28. Lu G D (2007). Anticancer effects of aloe-emodin on HepG2 cells: cellular and proteomic studies. *Proteomics. Clin. Appl.*, 1:410-419.
29. Cardenas C (2006). Evaluation of the anti-angiogenic effect of aloe-emodin. *Cell. Mol. Life. Sci.*, 63:3083-3089.

Tables

Table 1. Activities of antioxidant enzymes in the urinary bladder of mice in different treatment groups.

Group	Activity of antioxidant enzyme			
	GST	GR	GP	CAT
I (Controls)	144 ± 3	143 ± 4	155 ± 5	104 ± 3
II (BSO)	100 ± 2 ^b	92 ± 4 ^b	122 ± 3 ^b	97 ± 2 ^b
III (CP)	115 ± 3 ^d	122 ± 5 ^d	139 ± 4 ^c	84 ± 3 ^d
IV (BSO+CP)	79 ± 3 ^{f,h}	86 ± 2 ^{f,h}	118 ± 3 ^{f,h}	82 ± 3 ^f
V (CP+PE)	153 ± 5 ^l	152 ± 5 ^l	162 ± 2 ^l	107 ± 5 ^l
VI (BSO+PE)	146 ± 3 ⁿ	149 ± 6 ⁿ	156 ± 4 ⁿ	113 ± 7 ⁿ
VII (BSO+CP+PE)	145 ± 4 ^q	148 ± 6 ^q	154 ± 4 ^q	104 ± 5 ^q

Values are means ± SE (n = 6). GST expressed as nmol CDNB conjugates/min/mg protein, GR as nmol NADPH oxidized/min/mg protein, and GP as nmol NADPH oxidized/min/mg protein. CAT activity is expressed as nmol H₂O₂ consumed/min/mg protein. Significant differences are indicated by bP < 0.01, dP < 0.01, cP < 0.05, and fP < 0.01 when compared to control animals. (Group I) nP < 0.01 when compared to Group II, hP < 0.01 and iP < 0.01 when compared to CP-treated animals (Group III), and qP < 0.01 when compared to Group IV.

Figures




Fig 1: Effect of *Aloe vera*, BSO, and CP on the lipid peroxidation in the urinary bladder of mice. Significant differences are indicated by bP < 0.01 and dP < 0.01 in Group II (BSO) and Group III (CP) treated animals, respectively and by fP < 0.01 in Group IV (BSO + CP), as compared to control animals (Group I). hP < 0.01 indicates significant levels for the BSO + CP group when compared to the CP group. lP < 0.01 and nP < 0.05 indicate significant differences of values for Group V (CP + PE) and Group VI (BSO + PE) when compared to Group III and Group II, respectively. qP < 0.01 when values for Group IV and Group VII were compared. Values are means ± SE (n = 6).




Fig 2: Effect of *Aloe vera*, BSO, and CP on GSH content in urinary bladder of mice. Significant differences are indicated by bP < 0.01 and dP < 0.01 in Group II (BSO) and Group III (CP), respectively, and fP < 0.01 in Group IV (BSO + CP) when compared to control animals (Group I). hP < 0.01 indicates significant changes in the BSO+CP group when compared to the CP group. lP < 0.01 and nP < 0.01 indicate significant differences in observations for Group IV (CP + PE) and Group VI (BSO + PE) when compared to the data obtained for the GSH levels of Groups III and II, respectively. qP < 0.01 when GSH data of Group IV was compared to that of Group VII. Values are means ± SE (n = 6).